Compare DexCom, Inc. (DXCM) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Xylem, Inc. — how do they compare? DexCom, Inc. trades at $77.11 (market cap $28.06B), while Xylem, Inc. trades at $124.88 (market cap $28.86B). The key difference: DexCom, Inc. and Xylem, Inc. are close in size by market cap, and Xylem, Inc. pays a 1.42% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | XYL | |
|---|---|---|
Market Cap | $28.06B | $28.86B |
Sector | Health | Industrials |
52-Week High | $89.53 | $152.95 |
52-Week Low | $54.84 | $106.34 |
Enterprise Value | $27.03B | $30.12B |
Dividend Yield | — | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
Xylem (XYL) trades at $125.26, up 3.05% over 24 hours, with a bullish technical signal and consistent earnings beats. Revenue grew from $5.5B in 2022 to $9.0B in 2025, with net margins expanding to 10.59%. Recent news highlights partnerships, leadership appointments, and a dividend declaration, reinforcing its position in water technology solutions.
Outlook remains positive with a consensus price target of $152, implying 21% upside. Risks include execution challenges and macroeconomic pressures, but strong cash flow and analyst support suggest long-term growth potential for investors focused on sustainable infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
